StreetInsider.com News Articles

Study on Lifeward's ReWalk exoskeleton shows long-term home use

Wed, 14 Oct 2026 08:04:20 -0400

Lifeward Ltd. (Nasdaq: LFWD) announced the publication of an independent peer-reviewed study examining long-term home use of its ReWalk Personal Exoskeleton in individuals with chronic paraplegia, according to a company statement.

The study, published in Spinal Cord Series and Cases, an official journal of the International Spinal Cord Society published by Springer Nature, evaluated seven individuals who used the ReWalk 6.0 Personal Exoskeleton at home following structured training. Participants used the device for a median of 33 months, with individual periods ranging from 20 to 45 months. The study was conducted at Centro Protesi Inail, the prosthetic center of the Italian

Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study

Wed, 14 Oct 2026 08:00:00 -0400

Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia

ReWalk was used for a median of 33 months, with no reported falls or exoskeleton-related fractures during the observation period; participants maintained 3,000+ steps per month, demonstrating sustained real-world utilization

Participants reported high satisfaction including improvements in quality of life, mental health, bowel and bladder management, as well as less pain

Long-term real-world evidence adds to the growing body of data supporting broader access, reimbursement and adoption of ReWalk

HUDSON, Mass. and YOKNEAM

Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study

Wed, 14 Oct 2026 08:00:00 -0400

Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia

Participants reported high satisfaction including improvements in quality of life, mental health, bowel and bladder management, as well as less pain

Long-term real-world evidence adds to the growing body of data supporting broader access, reimbursement and adoption of ReWalk

HUDSON, Mass. and YOKNEAM

Form 8-K Lifeward Ltd. For: Oct 04

Thu, 08 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261008/27167363.html

Form 8-K Lifeward Ltd. For: Oct 01

Thu, 01 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261001/27132130.html

Form ARS Lifeward Ltd. For: Sep 25

Fri, 25 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260925/27108011.html

Form DEF 14A Lifeward Ltd. For: Sep 25

Fri, 25 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260925/27107990.html

Form PRE 14A Lifeward Ltd. For: Sep 15

Tue, 15 Sep 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260915/27065907.html

Form 8-K Lifeward Ltd. For: Sep 15

Tue, 15 Sep 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260915/27065814.html

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

Tue, 15 Sep 2026 08:00:00 -0400

Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

Tue, 15 Sep 2026 08:00:00 -0400

Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Zamir Haggai

Thu, 10 Sep 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27046266.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Zamir Haggai

Thu, 10 Sep 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260910/27046237.html

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Tue, 08 Sep 2026 08:30:00 -0400

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website.

The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, leverage its reimbursement infrastructure, and expand its capital-efficient distribution network. It also highlights the Company's recent commercial performance, product development pipeline and strategic partnership with Oramed Pharmaceuticals

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Tue, 08 Sep 2026 08:30:00 -0400

Lifeward names interim CEO and CFO amid leadership change

Mon, 31 Aug 2026 16:15:21 -0400

Lifeward Ltd. (Nasdaq: LFWD) announced the appointment of Josh Hexter as Interim Chief Executive Officer, effective September 1, 2026, and Rami Aviram as Chief Financial Officer, effective November 1, 2026, according to a company statement.

Hexter succeeds Mark Grant, who is leaving Lifeward to pursue other opportunities. Grant will remain as a consultant through September 30, 2026 to assist with the transition. Hexter brings nearly three decades of life sciences experience, including roles as Chief Operating and Business Officer of Oramed Pharmaceuticals, Chief Business Officer of BrainsWay, and Executive Director of Corporate In-Licensing at BioLineRx. He also founded Biosensor Systems Design,

Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer

Mon, 31 Aug 2026 16:15:00 -0400

Experienced leadership team to build on established commercial platform and accelerate Lifeward’s next phase of growth with continuity of strategy

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of Josh Hexter as Interim Chief Executive Officer effective September 1, 2026 and Rami Aviram as Chief Financial Officer effective November 1, 2026.

Hexter succeeds Mark Grant, who has chosen to leave Lifeward to

Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer

Mon, 31 Aug 2026 16:15:00 -0400

Experienced leadership team to build on established commercial platform and accelerate Lifeward’s next phase of growth with continuity of strategy

Hexter succeeds Mark Grant, who has chosen to leave Lifeward to

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998250.html

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998250.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998102.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998102.html

Form 4 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260824/26969054.html

Form 4 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260824/26969054.html

Form 3 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260824/26969037.html